![](/img/cover-not-exists.png)
CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE (FLT3+) ACUTE MYELOID LEUKEMIA (AML): A FRENCH PERSPECTIVE
Cariou, C., Tremblay, G., Dolph, M., Brandt, P.S., Forsythe, A.Volume:
21
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.09.023
Date:
October, 2018
File:
PDF, 639 KB
2018